NCT02158520 - Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 18, 2013

Primary Completion Date

May 24, 2017

Study Completion Date

October 30, 2019

Conditions

Metastatic MelanomaMucosal MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7Stage IV Uveal Melanoma AJCC v7Unresectable Melanoma

Interventions

BIOLOGICAL

Bevacizumab

Given IV

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nab-paclitaxel

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (13)

14263

Roswell Park Cancer Institute, Buffalo

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

49503

Cancer Research Consortium of West Michigan NCORP, Grand Rapids

51101

Siouxland Regional Cancer Center, Sioux City

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53792

University of Wisconsin Hospital and Clinics, Madison

54301

Saint Vincent Hospital Cancer Center Green Bay, Green Bay

55416

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park

55905

Mayo Clinic, Rochester

60612

University of Illinois, Chicago

68106

Missouri Valley Cancer Consortium, Omaha

94117

Saint Mary's Medical Center, San Francisco

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER